Palomar (NASDAQ:PLMR – Free Report) had its price target boosted by Keefe, Bruyette & Woods from $162.00 to $166.00 in a research report released on Wednesday,Benzinga reports. Keefe, Bruyette & Woods currently has an outperform rating on the stock.
A number of other research firms have also recently weighed in on PLMR. Weiss Ratings raised Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 18th. JPMorgan Chase & Co. reduced their target price on shares of Palomar from $160.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, May 26th. Piper Sandler decreased their target price on shares of Palomar from $151.00 to $132.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Finally, Zacks Research downgraded shares of Palomar from a “strong-buy” rating to a “hold” rating in a report on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Palomar currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.50.
View Our Latest Research Report on PLMR
Palomar Price Performance
Palomar (NASDAQ:PLMR – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.17 by $0.14. The firm had revenue of $278.94 million during the quarter, compared to analysts’ expectations of $557.79 million. Palomar had a net margin of 20.11% and a return on equity of 22.62%. The firm’s quarterly revenue was up 59.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.87 earnings per share. As a group, equities research analysts anticipate that Palomar will post 8.93 earnings per share for the current fiscal year.
Insider Activity
In other Palomar news, President Jon Christianson sold 6,863 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $139.50, for a total transaction of $957,388.50. Following the completion of the sale, the president owned 66,478 shares in the company, valued at $9,273,681. This represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Timothy Carter sold 480 shares of the company’s stock in a transaction on Sunday, June 28th. The stock was sold at an average price of $124.29, for a total value of $59,659.20. Following the sale, the insider owned 1,670 shares of the company’s stock, valued at $207,564.30. This trade represents a 22.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 22,977 shares of company stock valued at $2,933,488. 3.70% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in Palomar by 49.1% in the 1st quarter. Royal Bank of Canada now owns 2,956 shares of the company’s stock worth $406,000 after buying an additional 974 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Palomar by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,427 shares of the company’s stock valued at $2,115,000 after acquiring an additional 791 shares during the period. NewEdge Advisors LLC acquired a new stake in Palomar during the 1st quarter valued at approximately $66,000. United Services Automobile Association purchased a new stake in shares of Palomar in the 1st quarter valued at $223,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Palomar by 11.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 72,661 shares of the company’s stock valued at $9,960,000 after acquiring an additional 7,754 shares during the last quarter. Institutional investors and hedge funds own 90.25% of the company’s stock.
Palomar News Summary
Here are the key news stories impacting Palomar this week:
- Positive Sentiment: Keefe, Bruyette & Woods raised its price target on Palomar Holdings (PLMR) to $166 from $162 and kept an Outperform rating, signaling continued confidence in the company’s earnings outlook. Benzinga
- Neutral Sentiment: Zacks Research made small downward tweaks to near-term and longer-dated earnings estimates, including Q1 2027 and Q2 2028, while keeping a Hold rating. These revisions are modest, but they suggest analysts are still refining expectations after the company’s recent guidance update.
- Neutral Sentiment: Zacks Research also trimmed its FY2027 EPS estimate slightly to $9.66 from $9.72, which is a minor change and unlikely to be a major stock driver on its own.
- Negative Sentiment: Investor sentiment may also be keeping an eye on insider selling: Palomar President Jon Christianson sold 6,863 shares in a pre-arranged 10b5-1 plan. While routine, insider sales can sometimes create caution among traders. InsiderTrades
- Negative Sentiment: Earlier analyst work also included price-target cuts from some firms, showing that not all Wall Street views are uniformly bullish even after Palomar’s recent earnings beat and guidance increase.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Further Reading
- Five stocks we like better than Palomar
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
